Your study objective is to assess effects of four drugs on a health outcome with reference to the effect of a control substance on a health outcome. It is not about influence of time on drug or drug on time. Both drug and time are predictors not the response. An effect is of a predictor on the response.
The main effect of time is negative, shown by the negative slopes of lines from Time 1 to Time 2. It means the health outcome decreased over time no matter which of the five medications to use. The main effects of four treatment-group indicators measure the difference between a treatment group and the control group at Time 1 before using any medication. They are all negative if the control group had the highest score to begin with.
If group assignment is completely random, we expect that the main effects of treatment group to be zero. Significant main effects of treatment group means systematic differences at the starting line, nonrandom group assignment, and a sample-selection bias that undermines causal inference. For sample-selection remedy in causal inference, see my answer at Seeking Assistance in Evaluating My Research Plan for Regression Analysis. You can also use measurements at Time 1 as a predictor instead of a response, to adjust for baseline differences. See Senn, S. (2006). Change from baseline and analysis of covariance revisited. Statistics in Medicine, 25(24), 4334–4344. https://doi.org/10.1002/sim.2682.
You are using the difference-in-difference design, except that you do it four times. For the interpretation of interaction effects in this design, see my answer at Frank Harrell's interpretation of interaction in regression results. In your case, nonsignificant interaction between time and treatment means that the effects of 4 tested drugs on the health outcome were no different from that of the control substance, shown by the parallelism among the five downward lines. It does not mean that the tested drugs have no effects but that the tested drugs have no additional effects that the control substance cannot reach. This is a collective F test. To compare each drug to the control, we need to use t tests on individual coefficients of the four interaction terms in a regression table.
If you are conducting noninferiority study to demonstrate that new drugs are no worse than the current standard, nonsignificant interaction is a desirable result. Note that nonsignificant difference does not necessarily mean noninferiority or equivalence. For the definition and determination, see U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, & Center for Biologics Evaluation and Research. (2016). Non-inferiority clinical trials to establish effectiveness: Guidance for industry. https://www.fda.gov/media/78504/download